Affordable Access

deepdyve-link
Publisher Website

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.

Authors
  • Kanda, Tatsuo1
  • Nirei, Kazushige2
  • Matsumoto, Naoki2
  • Higuchi, Teruhisa2
  • Nakamura, Hitomi2
  • Yamagami, Hiroaki2
  • Matsuoka, Shunichi2
  • Moriyama, Mitsuhiko2
  • 1 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan. [email protected] , (Japan)
  • 2 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan. , (Japan)
Type
Published Article
Journal
World journal of gastroenterology
Publication Date
Dec 14, 2017
Volume
23
Issue
46
Pages
8120–8127
Identifiers
DOI: 10.3748/wjg.v23.i46.8120
PMID: 29290649
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The recent development of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) infection could lead to higher sustained virological response (SVR) rates, with shorter treatment durations and fewer adverse events compared with regimens that include interferon. However, a relatively small proportion of patients cannot achieve SVR in the first treatment, including DAAs with or without peginterferon and/or ribavirin. Although retreatment with a combination of DAAs should be conducted for these patients, it is more difficult to achieve SVR when retreating these patients because of resistance-associated substitutions (RASs) or treatment-emergent substitutions. In Japan, HCV genotype 1b (GT1b) is founded in 70% of HCV-infected individuals. In this minireview, we summarize the retreatment regimens and their SVR rates for HCV GT1b. It is important to avoid drugs that target the regions targeted by initial drugs, but next-generation combinations of DAAs, such as sofosbuvir/velpatasvir/voxilaprevir for 12 wk or glecaprevir/pibrentasvir for 12 wk, are proposed to be potential solution for the HCV GT1b-infected patients with treatment failure, mainly on a basis of targeting distinctive regions. Clinicians should follow the new information and resources for DAAs and select the proper combination of DAAs for the retreatment of HCV GT1b-infected patients with treatment failure.

Report this publication

Statistics

Seen <100 times